Quality of life in patients with chronic obstructive pulmonary disease: Which drugs help most?

BioDrugs

Volumn 13, Issue 2, 2000, Pages 127-133

  Chavannes, Niels H ^a   Van Schayck, Constant P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DYSPNEA; EXERCISE TOLERANCE; HEART DISEASE; HUMAN; HYPOXEMIA; LUNG FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREMOR;

EID: 0034100872     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013020-00006     Document Type: Review

References (50)

1. 1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76
2. 2. Liu B-Q. Peto R, Chen Z-M, et al. Emerging hazards in China: retrospective proportional mortality study of one million deaths. BMJ 1998; 317: 1411-22
3. 3. Feinleib M, Rosenberg HM, Collins JG, et al. Trends in COPD and mortality in the United States. Am Rev Respir Dis 1989; 140: S9-S18
4. 4. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989; 262: 907-13
5. 5. Osman IM, Godden DJ, Friend JA, et al. Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67-71
6. 6. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120
7. 7. Pearson MG, Alderslade R, Allen SC. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 Suppl. 5: S1-28
8. 8. Siafakas NM, Vermeire P, Pride P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J 1995; 8: 1398-1420
9. 9. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996; 334: 835-40
10. 10. Schayck van CP, Rutten MPHM, Doorslaer van EKA, et al. Two-year bronchodilator treatment in patients with mild airflow obstruction: contradictory effects on lung function and quality of life. Chest 1992; 102: 1384-91
11. 11. Schayck van CP. Measurement of quality of life in patients with chronic obstructive pulmonary disease. Pharmacoeconomics 1997; 11: 13-18
12. 12. Tsukino M, Nishimura K, Ikeda A, et al. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest 1996; 110: 896-903
13. 13. Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease. Am J Respir Crit Care Med 1997; 156: 1032-9
14. 14. Toshima MT, Kaplan RM, Ries AL. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status. Health Psychol 1990; 9: 237-52
15. 15. Bergner M, Hudson LD, Conrad DA, et al. The cost and efficacy of home care for patients with chronic lung disease. Med Care 1988; 26: 566-79
16. 16. Wijkstra PJ, Altena van J, Kraan et al. Quality of life in patients with chronic obstructive pulmonary disease after rehabilitation at home. Eur Respir J 1994; 7: 269-73
17. 17. Wijkstra PJ, Ten Vergert EM, Altena van R, et al. Long term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 824-8
18. 18. Guyatt GH, Herman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-8
19. 19. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am J Rev Respir Dis 1992; 145: 1321-7
20. 20. Hyland ME, Bott J, Singh S, et al. Domains, constructs and the development of the breathing problems questionnaire. Qual Life Res 1994 3: 245-56
21. 21. Hajiro T, Nishimura K, Tsukino M, et al. Comparison of discriminative properties among disease-specific qyestionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 785-90.
22. 22. Wijkstra PJ, Ten Vergert EM, Mark van der ThW, et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 1994; 49: 465-7
23. 23. Hajiro T, Nishimura K, Jones PW, et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1874-8
24. 24. Mahler D, Weinber D, Wells C, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8
25. 25. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6
26. 26. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-74
27. 27. Mahler DA, Matthay RA, Snyder PE, et al. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airways disease. Am Rev Respir Dis 1985; 131: 22-5
28. 28. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62-70
29. 29. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9
30. 30. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65
31. 31. Maesen BLP, Westermann CJJ, Duurkens VAM, et al. Formoterol induced responses in non-reversible chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: A282
32. 32. Tutluoglu B, Gurbuz N, Sahin S, et al. Effects of short term usage of formoterol on six minute walking test in COPD patients. Eur Resp J 1997; 10 Suppl. 25: 65S
33. 33. Barnes PJ, Belvisi MG, Mak JCW, et al. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995; 56: 853-9
34. 34. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD) (Dutch Study Group). Eur Respir J 1995; 8: 1506-13
35. 35. Vestbo J, Sörensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23
36. 36. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53
37. 37. Calverley PMA, Burge PS, Jones PW, et al. Effect of 3 years treatment with fluticasone propionate in patients with moderately-severe COPD. Am J Respir Crit Care Med 1999; 159: A524
38. 38. Spencer S, Anie K, Calverley PMA, et al. Rate of health status decline is reduced in COPD patients treated with fluticasone compared to placebo. Am J Respir Crit Care Med 1999; 159: A522
39. 39. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 1418-22
40. 40. Niewohner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7
41. 41. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-60
42. 42. Rasmussen JB, Gleenow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-5
43. 43. Boman G, Bäcker U, Larsson S, et al. Oral acteylcysteine reduces exacerbation rate in chronic bronchitis: report of trial organised by Swedish Society for Pulmonary Diseases. Eur Respir J 1983; 64: 405-15
44. 44. Multicentre Study Group. Long-term oral acetylcysteine in chronic bronchitis: a double-blind controlled study. Eur J Respir Dis 1980; 61 Suppl. 111: 93-108
45. 45. Schayck CP van, Dekhuijzen PNR, Gorgels WJMJ, et al. Are anti-oxidant and ant-inflammatory treatment effective in different subgroups of COPD?: a hypothesis. Respir Med 1998; 92: 1259-64
46. 46. Ede van L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999; 54: 688-92
47. 47. Prigatano GP, Wright EC, Levin D. Quality of life and its predictors in patients with mild hypoxaemia and chronic obstructive pulmonary disease. Arch Intern Med 1984; 144: 1613-19
48. 48. Borson S, McDonald GJ, Gayle T, et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190-201
49. 49. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91
50. 50. Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax 1996; 51: 44-7